Financial Performance - gategroup generated revenues of EUR 5.61 billion for the financial year ending December 31, 2025, an increase from EUR 5.47 billion in 2024 [1] - EBITDA reached EUR 467 million, up from EUR 410 million in 2024, resulting in an EBITDA margin of 8.3 percent compared to 7.5 percent in the previous year [1] - Net debt/EBITDA ratio improved to 3.25x from 3.74x in 2024, indicating a stronger balance sheet [1] - Gross capital expenditures for the period amounted to EUR 88 million, an increase from EUR 72 million in 2024 [1] Currency Transition - gategroup is transitioning its reporting currency from Swiss Francs (CHF) to Euros (EUR) to better align with its revenue generation and global operations [2] - The 2025 annual report will be published in EUR in early April 2026 after the completion of the full audit [2] Strategic Initiatives - gategroup successfully completed a bond repurchase tender for its CHF 350 million bond maturing in February 2027, with CHF 92 million in bonds tendered and accepted [3] - The company is evaluating a range of strategic options to support future growth, including a potential public listing, although no decision has been made yet [4] Company Overview - gategroup is a leading global provider of airline catering, retail-on-board, and hospitality products and services, headquartered in Zurich, Switzerland [5] - The company serves millions of passengers through a network of nearly 300 locations in over 68 countries, partnering with leading airlines to enhance travel experiences [5]

Core Viewpoint - Idorsia Ltd has announced a repurchase offer for its outstanding convertible bonds as part of a broader restructuring strategy aimed at enhancing its financial position and operational efficiency [1][2]. Group 1: Repurchase Offer Details - The repurchase offer targets CHF 200 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [1]. - Approximately 87.5% of the CB 2025 and 90.1% of the CB 2028 bondholders have entered into a lockup agreement to support the restructuring and participate in the repurchase offer [3]. - The main offer period for the repurchase is set to begin on July 10, 2025, and conclude on August 7, 2025, with a minimum acceptance condition of 85% of the total issued nominal value required for the offer to proceed [4]. Group 2: Participation and Documentation - Bondholders can access the repurchase offer documentation and participate through Kroll Issuer Services Ltd, which will also facilitate a new money facility for eligible bondholders [5]. - Detailed instructions and eligibility criteria for participation in both the repurchase offer and the new money facility are available in the repurchase offer documentation [5]. Group 3: Company Overview - Idorsia Ltd aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [7]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising development pipeline and partnerships to maximize portfolio value [8].